CisionVision Receives Prestigious ARPA-H Funding
Teams that will contribute to this groundbreaking project include
"We are honored to receive this award and work with a distinguished group of researchers to drive innovations in surgical imaging," said
"I am excited to collaborate with a multidisciplinary team of experts advancing the frontier of surgical imaging technology," said
"With the Precision Surgical Interventions program, we're seeking to fundamentally change how surgery is done."
The collaboration involves:
- Stanford Medicine: Recognized as a center of academic excellence and healthcare innovation, Stanford will accelerate the integration of these breakthrough technologies into clinical practice.
- Johns Hopkins Medicine: A leader in medical research, Johns Hopkins Medicine will focus on clinical studies and the application of advanced visualization technologies in real-world surgical settings.
- Endeavor Health: As a Chicagoland-based integrated health system and national leader in laboratory innovation, Endeavor Health will facilitate the implementation and evaluation of these technologies in a clinical environment.
- University of Notre Dame: With expertise in artificial intelligence and biomedical imaging, Notre Dame will transform surgical data into clinical insights for more precise and safer surgery.
Learn more: https://arpa-h.gov/news-and-events/arpa-h-announces-awards-develop-novel-technologies-precise-tumor-removal
Media Contact
About CisionVision
CisionVision is a medical device company dedicated to advancing the field of medical imaging. With a commitment to excellence and collaboration, CisionVision works with top institutions to bring innovative solutions to surgeons, pathologists, pathologist's assistants, and other clinicians to improve patient outcomes worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cisionvision-receives-prestigious-arpa-h-funding-302223529.html
SOURCE Cision Vision
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
- The Board of Directors of IQM Quantum Computers Plc has resolved to establish new share-based long-term incentive plans for the employees of the group
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share